A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis with rVWF in Severe Von Willebrand Disease

August 02, 2018
https://clinicaltrials.gov/ct2/show/NCT02973087
Hematology Non Malignant
Principal Investigator: Philip Kuriakose, MD
Prophylaxis, rVWF, Von Willebrand Disease
Accepting Participants